New findings on presentation and outcome of patients with adrenocortical cancer: results from a national cohort study

Context: Due to the rarity of adrenocortical cancer (ACC), only a few population-based studies are available and they reported limited details in the characterization of patients and their treatment. Objective: To describe in a nation-wide cohort the presentation of ACC patients, treatment strategies and potential prognostic factors. Methods: Retrospective analysis of 512 ACC patients, diagnosed in twelve referral centers in Italy from January 1990 to June 2018. Results: ACC diagnosed as incidentalomas accounted for overall 38.1% of cases, with a frequency that increases with age and with less aggressive pathological features than symptomatic tumors. Women (60.2%) were younger than men, had smaller tumors, which more frequently secreted hormones. Surgery was mainly done with an open approach (72%), and after surgical resection, 62.7% of patients started adjuvant mitotane therapy. Recurrence after tumor resection occurred in 56.2% of patients. In patients with localized disease, cortisol secretion, ENSAT stage III, Ki67% and Weiss score were associated with an increased risk of recurrence, while margin-free resection, open surgery and adjuvant mitotane treatment were associated with reduced risk. Death occurred in 38.1% of patients and recurrence-free survival (RFS) predicted overall survival (OS). In localized disease, age, cortisol secretion, Ki67%, ENSAT stage III, and recurrence were associated with increased risk of mortality.ACCs presenting as adrenal incidentalomas showed prolonged RFS and OS. Conclusions: Our study shows that ACC is a sex-related disease and demonstrates that an incidental presentation is associated with a better outcome. Given the correlation between RFS and OS, RFS may be used as a surrogate end-point in clinical studies.